BPC-157 and TB-500: the Wolverine stack and what the research shows

The Wolverine stack is an online nickname for taking BPC-157 and TB-500 together. The name borrows from the comic-book character who heals quickly, and it is a marketing label, not a scientific one. No paper we found uses the term. In searches the pair is often typed without hyphens, as BPC157 TB500.

In practice the Wolverine stack peptide is sold in two ways. Some buyers get two separate vials. More often now, suppliers sell a single pre-mixed vial containing both. Listings we track include names such as "BPC/TB500 (Wolverine) 10/10mg", "BPC/TB500 Blend 5+5mg" and "Wolverine Blend (BPC&TB500)" in 10 mg and 20 mg sizes. These are research-chemical products, not medicines, and the label contents are the seller's claim. Our guide to what research peptides are explains what that label does and does not mean.

The two molecules are unrelated. BPC-157 is a 15-amino-acid peptide first described by a group at the University of Zagreb and studied mostly by that group ^{[1] [5]}. TB-500 is a seven-amino-acid fragment, Ac-LKKTETQ, copied from the natural protein thymosin beta-4. Anti-doping chemists in Ghent identified this fragment as the content of products sold as TB-500 ^[9].

The case for pairing them rests on the idea that they act by different routes, so their effects might add up. In laboratory work BPC-157 increased blood-vessel formation. It raised the expression and activation of VEGFR2, a receptor for the growth factor VEGF, and switched on the Akt–eNOS signalling pathway ^[2]. In rat tendon cells it did not make cells divide faster, but it did help them survive oxidative stress and migrate, through the FAK–paxillin pathway ^[3].

Thymosin beta-4, the parent protein of TB-500, binds actin, a building block of the cell skeleton, and stimulates cell migration. In a 1999 rat wound study, thymosin beta-4 increased re-epithelialisation by 42% over saline at four days and by up to 61% at seven days ^[19]. In a 2003 mouse study, the seven-amino-acid stretch LKKTETQ promoted skin repair in aged mice to a degree comparable with the full protein ^[10]. That is the main published evidence that the fragment itself is active.

So the theory is angiogenesis from one peptide and cell migration from the other. That is a hypothesis built from separate cell and animal studies of each molecule. Until 2026 nobody had tested the combination in a controlled experiment, and the one study that has done so did not find that the effects added up.

In July 2026, a group from Istanbul published the first controlled study to compare BPC-157, TB-500 and BPC-157 and TB-500 given together ^[8]. Thirty-two male rats had their Achilles tendons cut and surgically repaired. They were randomly split into four groups of eight: no treatment, BPC-157 at 10 µg/kg/day, TB-500 at 60 µg/kg/day, or both. The peptides were injected into the abdominal cavity daily for four weeks, and the tendons were then tested for strength or examined under the microscope.

The BPC-157 group and the TB-500 group both had higher maximum load to failure than the untreated controls, but the difference was statistically significant only for TB-500. Under the microscope, TB-500 produced significantly better total scores on both tissue-grading systems used (Bonar and Movin). The combination group was significantly better than controls on the Movin score only. BPC-157 alone gave numerically better scores that did not reach significance for the totals. The authors reported that combining the two peptides "did not confer additional benefits" compared with either alone ^[8].

This result needs care in both directions. It is one small rat study with eight animals per group, and the animals were split between strength testing and tissue analysis, so each measurement used fewer animals still. It used one dose of each peptide for one period. The abstract describes TB-500 as synthetic thymosin beta-4 and does not give its sequence, so we cannot confirm which molecule was in the vials. Even so, it is the only direct test of the combination, and it does not support the claim that the two work better together. For BPC-157, the result was weaker than the 2003 Zagreb study, which reported better strength, function and healing with BPC-157 at the same 10 µg/kg dose ^[1].

In the TB500 vs BPC-157 comparison, the biggest difference is the kind of evidence behind each name. Nearly all BPC-157 research used BPC-157 itself, though most of it came from one laboratory ^[5]. A 2025 systematic review found 36 studies, 35 of them preclinical, and rated the evidence as level IV and V ^[5]. For TB-500, most of the work people cite was done with full-length thymosin beta-4, a 43-amino-acid protein, not with the seven-amino-acid fragment that is sold.

That matters because the fragment may not behave like the protein. A 2024 study from a Korean doping control laboratory tracked how TB-500 is broken down. Its main metabolite in rats was Ac-LK, and only the metabolite Ac-LKKTE, not TB-500 itself, significantly improved wound closure in cultured fibroblasts. The authors suggested that wound-healing activity reported for TB-500 may come from that metabolite ^[11].

Human data are thin for both. BPC-157 has three small uncontrolled pilot reports from private US clinics ^[6]. TB-500 has none; the phase 1 and 2 trials that exist gave pharmaceutical full-length thymosin beta-4, for example by intravenous infusion in healthy volunteers, where adverse events were infrequent and mild or moderate ^[12]. Those results do not transfer to the fragment.

Pharmacokinetics also differ. Intact BPC-157 had an elimination half-life of under 30 minutes after injection in rats and dogs ^[4]. No half-life for TB-500 in people has been published. In rats, its short-lived metabolite Ac-LK peaked within six hours and the longer-lived metabolite Ac-LKK was still detectable in urine at 72 hours ^[11].

The only published human report involving both peptides is a 2021 retrospective chart review from a private clinic in Florida ^[7]. It looked back at 16 people who had received knee injections. Twelve received BPC-157 alone, and 11 of them reported significant improvement in pain. Four received injections of BPC-157 and thymosin beta-4 (the abstract says TB4, not TB-500), and three of those four reported improvement.

This does not show that the combination works. Pain was assessed by a telephone survey months after the injections, with no validated scoring tool, no control group and no blinding ^[7]. Four people is too few to draw any conclusion. A 2025 review of BPC-157 for musculoskeletal healing concluded that human data are "extremely limited" and that it should be treated as investigational ^[6]. A 2026 Sports Medicine review covering both BPC-157 and TB-500 reached a similar view: favourable animal results, but scarce rigorous human safety data ^[14].

Searches for Wolverine stack dosage and dosage charts are common, so it is worth being precise about what exists. The only study of the two peptides given together used 10 µg/kg/day of BPC-157 and 60 µg/kg/day of TB-500, injected into the abdominal cavity of rats for four weeks ^[8]. The 2003 Zagreb tendon study gave BPC-157 at 10 µg/kg, 10 ng/kg or 10 pg/kg daily by the same route ^[1]. These are animal doses. They should not be converted to human doses, and no study has tested whether any ratio of the two is better than another.

No human dose of BPC-157 TB-500 blends has been established. The knee report did not give a standard dose in its abstract ^[7]. The phase 1 trial of full-length thymosin beta-4 gave 42 mg to 1,260 mg intravenously ^[12], but that is a different, much larger molecule and says nothing about TB-500. Dosage charts found online are not drawn from any published trial of the blend.

Blend labels create a specific arithmetic point. A vial sold as 10 mg BPC-157 plus 10 mg TB-500 contains the two in a fixed 1:1 ratio by mass, so any volume drawn from it contains equal amounts of each. After mixing, the concentration of each peptide is simply its labelled mass divided by the volume of water added. Our peptide calculator does that sum, and our guide to bacteriostatic water explains what the diluent is. Neither tells you what amount, if any, is appropriate.

There are no controlled human safety data for the Wolverine stack. The three BPC-157 pilot reports described no adverse events, but they involved about 30 people in total and short follow-up ^[6]. The 2025 systematic review found no clinical safety data for BPC-157 and warned of possible harm from unregulated manufacturing and contamination ^[5]. There are no human safety data for TB-500 at all.

The FDA placed both BPC-157 and TB-500 in category 2 of its compounding policy, the list of bulk substances that may present significant safety risks, citing concerns including immune reactions and peptide-related impurities. The nominations were later withdrawn, and the FDA now lists both among substances previously in category 2. Withdrawal is not an authorisation ^[15].

Product quality is a real issue. French anti-doping researchers found that products sold online as TB500 and TB1000 did not consistently match their descriptions ^[13]. A pre-mixed vial adds a second unknown, because a buyer cannot tell from the label how much of each peptide is actually present. BPC-157 also promotes blood-vessel growth in laboratory models ^[2], and whether that could matter for existing tumours has not been studied in people. Independent testing is the only way to check contents. See how to read a peptide COA and our list of third-party tested suppliers.

Neither peptide is an approved medicine. On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee considered BPC-157 and TB-500, among others, for the list of substances US pharmacies may compound. The FDA's meeting page had posted no outcome when we checked, and the FDA has not acted ^[16]. An advisory committee meeting is not an approval.

Outside the US, Health Canada's April 2026 advisory named both BPC-157 and TB-500 among seized unauthorised peptides and said research-use labelling does not make such products legal ^[18]. In Australia, both are Schedule 4 poisons listed in Appendix D of the Poisons Standard, which cannot be possessed without authority ^[20]. In New Zealand, Medsafe classifies both as prescription medicines ^[21]. The rules for your country are on our legal status pages, including the UK and Australia.

For athletes the answer is simple. WADA names BPC-157 under S0 (non-approved substances) and "thymosin-β4 and its derivatives e.g. TB-500" under S2, so both are prohibited at all times, and any blend containing either is too ^[17].

Prices for BPC-157 and TB-500 are tracked separately on our BPC-157 price page and TB-500 price page, with country pages such as BPC-157 in the UK. Blends are usually listed under one of the two. When comparing a blend with two separate vials, compare the price per milligram of each peptide rather than the price per vial. Our guide to peptide prices explains how we normalise them.